Evaluating the effectiveness of surgical systems for treating open-angle glaucoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study analyzes the real-world efficacy of the Hydrus Microstent combined with the OMNI Surgical System and Phacoemulsification in patients with open-angle glaucoma. It focuses on patients who have undergone these procedures and have at least three years of follow-up data. The study aims to assess how well this combination treatment lowers intraocular pressure (IOP) in a diverse patient population. By utilizing retrospective data, the study seeks to provide insights into the long-term outcomes of these surgical interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects with h/o CEIOL/OMNI/Hydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data
* have Glaucoma

Exclusion Criteria:

* Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
* Patients with refractory CME or CME persisting 3 months or more post-operatively
* Patients with incomplete IOP, medication logs or VF data within post-operative period
* Prior incisional surgery or MIGS

Where it's running

• Barnet Dulaney Perkins Eye Center
  Mesa, Arizona, United States Recruiting

Study contacts

• Principal investigator: Christine Funke, Medical Doctor — Barnet Dulaney Perkins Eye Centers
• Study coordinator: Derek J Arnson, Master of Education
• Email: derek.arnson@researchavp.com
• Phone: 4804201005

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rocklatan versus latanoprost for 24-hour eye pressure control in open-angle glaucoma and ocular hypertension

  This trial tests whether a combination eye drop (Rocklatan) lowers eye pressure over 24 hours more than latanoprost alone in adults with open-angle glaucoma or ocular hypertension.

  Recruiting Phase 4 Mayo Clinic · Rochester, Minnesota · NCT07325240

• Patient quality of life after different glaucoma surgeries

  This project uses the NEI-VFQ-25 vision questionnaire to see if adults who have PreserFlo MicroShunt, trabeculectomy, or non-penetrating deep sclerectomy report different quality of life after surgery.

  Recruiting Hospices Civils de Lyon · Lyon · NCT07303257

• iStent infinite plus iDose TR for moderate-to-severe open-angle glaucoma

  This trial will see if placing an iStent infinite device together with an iDose TR travoprost implant can lower eye pressure and reduce glaucoma eye drops for people with moderate to severe open-angle glaucoma not controlled by medication or laser.

  Recruiting Phase 4 Wills Eye · Philadelphia, Pennsylvania · NCT07228221

• Eye-surface inflammation after replacing nightly preserved glaucoma drops with a Durysta implant

  We will try a single Durysta intracameral implant to see if cutting back nightly preserved glaucoma drops reduces eye-surface inflammation in people with open-angle glaucoma or ocular hypertension who are pseudophakic and have signs of surface damage.

  Recruiting Phase 4 University of Miami · Miami, Florida · NCT07217678

• Vitamin mix for glaucoma patients

  This study is testing if a mix of certain vitamins can help protect the eyes and slow vision loss in people with glaucoma.

  Recruiting Karolinska Institutet · Stockholm, Stockholm County and 1 other locations · NCT06885827

• Comparing the effectiveness of two glaucoma treatments

  This study is testing whether two new glaucoma treatments, Simbrinza and Rocklatan, work better than the current options, Cosopt and Latanoprost, for adults with mild to moderate open-angle glaucoma.

  Recruiting Phase 4 Prairie Eye Center · Springfield, Illinois · NCT06883123

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.